Edwards Lifesciences Corp
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $6.1B | $5.4B | $5.0B | $4.5B | $5.2B |
| Cost of revenue | $1.3B | $1.1B | $978.4M | $723.7M | $1.2B |
| Gross profit | $4.7B | $4.3B | $4.0B | $3.7B | $4.0B |
| Selling, general & administrative | $2.1B | $1.8B | $1.6B | $1.4B | $1.5B |
| Research and development | $1.1B | $1.1B | $962.9M | $843.6M | $903.1M |
| Operating income | $1.3B | $1.4B | $1.3B | $1.5B | $1.7B |
| Interest expense | $20.4M | $19.8M | $17.6M | $19.2M | $18.4M |
| Pretax income | $1.3B | $1.5B | $1.4B | $1.5B | $1.7B |
| Income tax expense | $216.9M | $152.1M | $152.4M | $195.5M | $198.9M |
| Net income | $1.1B | $4.2B | $1.4B | $1.5B | $1.5B |
| Balance Sheet | |||||
| Cash and equivalents | $2.9B | $3.0B | $1.1B | $769.0M | $862.8M |
| Current assets | $6.7B | $6.3B | $4.0B | $3.1B | $3.2B |
| Total assets | $13.7B | $13.1B | $9.4B | $8.3B | $8.5B |
| Current liabilities | $1.8B | $1.5B | $1.2B | $1.0B | $1.0B |
| Total liabilities | $3.4B | $3.0B | $2.6B | $2.5B | $2.7B |
| Stockholders' equity | $10.3B | $10.0B | $6.7B | $5.8B | $5.8B |
| Cash Flow Statement | |||||
| Cash from operations | $1.6B | $542.3M | $895.8M | $1.2B | $1.7B |
| Depreciation and amortization | $156.6M | $155.2M | $144.9M | $139.6M | $134.8M |
| Stock-based compensation | $158.1M | $162.3M | $139.4M | $126.8M | $109.3M |
| Capital expenditure | $260.2M | $252.4M | $253.0M | $244.6M | $325.8M |
| Free cash flow | $1.3B | $289.9M | $642.8M | $973.6M | $1.4B |
| Share repurchases | $893.4M | $1.2B | $879.6M | $1.7B | $512.8M |
| Impairments | $186.9M | $0 | $0 | $55.1M | $4.0M |
Shares outstanding 575.8M · Free float 99.7%
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.